Troubled blood-testing company Theranos earned precisely nothing in 2015 and 2016


The rise and precipitous fall of biotech startup Theranos has been something to see. The company was famous for Edison – its platform which allowed physicians to run an entire battery of tests on a single sample of blood. Except it didn’t work. Not really. The fundamental failings of the Edison system were exposed in an explosive Wall Street Journal piece published in October 2015. As a result of that article, Theranos is being sued by its biggest and most high-profile customer, Wallgreens, as well as one of its principal investors, Partner Fund Management, for $240 million. Theranos, which was valued…

This story continues at The Next Web

Read Original:
Related Stories: